Whether AT 1 (angiotenin II type 1) receptor blockade can prevent the decrease in conduit artery FMD (flow-mediated dilatation) during NOS (nitric oxide synthase) inhibition by alternative endothelial pathways has not been explored previously in humans. In 12 healthy subjects, we measured radial artery diameter (echotracking) and flow (Doppler) during FMD induced by sustained reactive hyperaemia during a control period and following NOS inhibition [1.5 mg · min
INTRODUCTION
The endothelium plays a crucial role in conduit artery FMD (flow-mediated dilatation) and participates in the control of arterial tone and trophicity by releasing vasoactive factors, mainly NO (nitric oxide) [1, 2] . A decrease in arterial NO availability is associated with abnormal vasomotion, smooth muscle cell proliferation and migration, monocyte adhesion and a procoagulant state that characterize endothelial dysfunction and contribute to the pathophysiology of cardiovascular diseases [3, 4] . An increasing number of studies have demonstrated that the local activation of the renin-angiotensin system participates in the development of endothelial dysfunction through the stimulation of the AT 1 (angiotensin II type 1) receptor subtype and the inactivation of NO [5] [6] [7] .
AT 1 receptor antagonists are specific agents that block the effects of angiotensin II mediated through AT 1 receptors, thus preserving the potential beneficial activity of AT 2 (angiotensin II type 2) receptors on vascular tone and BP (blood pressure) [6, 8] . In humans, despite some conflicting results [9, 10] , the administration of AT 1 receptor antagonists enhances FMD of conduit arteries in cardiovascular diseases associated with endothelial dysfunction [11] [12] [13] [14] [15] . However, the mechanisms of action of these agents on endothelial function, to our knowledge, have not been fully investigated in humans. In patients with coronary artery disease, the beneficial effect of AT 1 receptor blockade on endothelial function of peripheral conduit arteries is mainly related to the increase in both NO and bradykinin availability [12, 14] . In addition, it has been demonstrated in animal models with hypertension or renal failure that chronic treatment with antagonists can also enhance endothelium-dependent dilatation of isolated mesenteric arteries during combined inhibition of NO and PGI 2 (prostacyclin) synthesis [16, 17] . Under these experimental conditions, this beneficial effect of AT 1 receptor blockade is due to the release of an EDHF (endothelium-dependent hyperpolarizing factor) [16, 17] that has not yet been identified, but could be related to CYP (cytochrome P450)-derived products [18] . In humans, whether or not AT 1 receptor blockade can prevent the decrease in conduit artery FMD during NO deficiency by an alternative endothelial pathway remains unknown.
In this context, the main aim of the present study was to evaluate the effect of the acute administration of an AT 1 receptor antagonist on the FMD of peripheral conduit arteries before and during NOS (NO synthase) inhibition in humans. Moreover, in an exploratory approach, we tested whether the effect of an AT 1 receptor antagonist on FMD during NO deficiency remains constant during the inhibition of PGI 2 and CYP-related product synthesis.
MATERIALS AND METHODS

Subjects
A total of 18 healthy male volunteers were included in this study. None had evidence of hypertension (BP > 140/ 90 mmHg), hyperlipidaemia (total serum cholesterol > 200 mg/dl) or clinical evidence of cardiovascular disease or diabetes on the basis of previous medical history and complete medical examination, normal ECG and recent routine laboratory tests. No participants were smokers or taking medication at the time of the study. The forearm volume was measured in each subject by using the waterdisplacement method based on Archimedes' principle, and drug infusion rates were normalized to 1 litre of tissue forearm by alteration of the drug concentration in the solvent while the pump speed of infusion was maintained constant. The research was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association and was approved by the Consultative Committee for the Protection of Persons Engaged in Biomedical Research of Haute-Normandie. All participants gave informed written consent after full explanation of the purpose, nature and risk of all of the procedures used.
Instrumentation
Measurements were performed at 08.00 hours, 1 h after a fat-free breakfast without tea or coffee, while subjects were supine in a quiet air-conditioned room, maintained at a constant temperature (22) (23) (24) • C). A 27-gauge needle was inserted under local anaesthesia (1 % lidocaine) into the brachial artery of the non-dominant arm to allow the local infusion of physiological saline and pharmacological agents at constant rate (1 ml/min). Systemic BP and HR (heart rate) were measured using a brachial cuff oscillometric device (Dinamap 8103; Critikon). Radial internal diameter, blood flow velocity and digital BP were measured continuously using a high-precision echotracking device (10 MHz; Nius 02; Asulab) coupled to a Doppler device (8 MHz; Doptek; Deltex) and a finger photoplethysmograph (Finapres 2300; Ohmeda), as described previously [1, [19] [20] [21] [22] [23] . This device allows the measurement of the internal diameter of the radial artery with a resolution of the diameter evolution of < 1 µm [23] . Radial artery flow was based on the measurement of velocity and diameter. In absence of a change in MBP (mean BP), variations in radial artery flow observed with the pharmacological agents reflect the changes in radial vascular resistance, which is usually calculated as the ratio of MBP to radial artery flow [24] .
Study protocols
Randomized double-blind placebo-controlled cross-over study: effect of AT 1 receptor blockade on radial artery FMD before and during NOS inhibition A total of 12 healthy subjects (23 + − 1 years) were examined on two separate days with a 2-week washout period between each treatment day. Subjects were allowed to rest for 30 min after instrumentation. HR and BP were then recorded, and telmisartan (80 mg/day) or placebo were administered. After 2 h, BP, HR and radial artery blood flow and diameter were recorded for 5 min. Subsequently, an arterial occlusion cuff placed on the wrist was inflated for 10 min at 180 mmHg and was deflated Radial artery FMD was calculated as the percentage change in radial artery diameter during hyperaemia. In addition, peak flow and the AUC of flow were determined to characterize the hyperaemic stimulus.
to allow reactive hyperaemia with continuous measurements of all of the parameters. Based on preliminary results, we used a 10 min occlusion protocol to induce a maximal increase in radial artery diameter [22] with a significant participation of NO [19] . After radial artery blood flow and diameter had returned to baseline, the subjects received SNP (sodium nitroprusside) at the incremental doses of 1.31, 2.62 and 5.24 mg · min
(5, 10 and 20 nmol · min −1 · l −1 ) for 3 min to assess endothelium-independent dilatation [21] . Once the radial artery diameter had returned to baseline, subjects received the NOS inhibitor l-NMMA (N G -monomethyl-l-arginine; Clinalfa) at a dose of 1.5 mg · min
This dose of l-NMMA has been shown to induce prolonged inhibition of NOS for at least 40 min and to block forearm and radial artery vasodilatation to acetylcholine administered at doses producing maximal regional effects without systemic haemodynamic changes [21] . At 5 min after l-NMMA infusion, all parameters were measured again at baseline and the same occlusion ischaemia and SNP infusion protocol was repeated. Baseline and peak measurements are mean values obtained during 15 and three cardiac cycles respectively. The continuous measurement of radial artery parameters allowed the maximal values of diameter and flow occurring after cuff deflation to be estimated precisely. Thus radial artery FMD was calculated as the percentage change in radial artery diameter in response to post-ischaemic hyperaemia with the peak diameter after cuff deflation and the basal diameter before cuff inflation ( Figure 1 ):
Moreover, because modifications in the hyperaemic stimulus influence the magnitude of radial artery FMD, we also measured parameters characteristic of this stimulus, i.e peak flow, representing the maximal value of flow after cuff deflation, and the AUC (area under the curve) of flow, representing the duration of the increase in flow ( Figure 1 ) [22] . Echotracking measurements were performed by the same observer and were read with the assistance of two other investigators, all blinded to the subjects and treatments.
Exploratory study: the role of PGI 2 and EDHF on radial artery FMD during AT 1 receptor blockade A total of six healthy subjects (23 + − 2 years) participated in a complementary open study. Radial artery FMD was evaluated in response to four reactive hyperaemia tests (wrist occlusion for 10 min) performed successively. First, the radial artery FMD was evaluated under control conditions prior to telmisartan administration. Subsequently, each subject received a single oral dose of telmisartan (80 mg) followed, 90 min later, by a single oral dose of aspirin (500 mg) to block vascular COX (cyclo-oxygenase) activity 30 min after administration and during the next 6 h [20, 25] . At 30 min after aspirin administration, a second reactive hyperaemia was performed. After an additional resting period of 30 min and the return of the measurements to baseline, subjects received l-NMMA at 1.5 mg · min
) for 7 min, followed by the third reactive hyperaemia to evaluate a possible interaction between PGI 2 and NO during FMD. Finally, after obtaining baseline measurements again, reactive hyperaemia was performed after the co-infusion for 7 min of l-NMMA, at the same dose used above, with fluconazole, a potent inhibitor of endothelial CYP 2C9 located in human arteries in the endothelium and identified as EDHF synthase [18] . Ex vivo experiments have demonstrated that CYP 2C9 produces 11,12-epoxyeicosatrienoic acid, which induces the hyperpolarization and relaxation of vascular smooth muscle cells [26] . In addition, we have demonstrated recently [20] using fluconazole that a CYP-derived EDHF is involved with NO in the control of the basal radial artery diameter. Fluconazole was infused at a dose of 0.37 mg · min
) to obtain a calculated local concentration, according to a radial artery flow at baseline and during reactive hyperaemia (10-100 ml/min), at least twice the in vitro K i of CYP 2C9 and with a weaker activity on other CYP enzymes [20, 27] .
Statistical analysis
Results are means + − S.E.M. In the randomized doubleblind study, the effect of treatments and l-NMMA on the parameters measured were analysed by ANOVA with treatment (placebo and telmisartan), periods (control and l-NMMA) and subjects as factors and MBP as a covariate. In addition, analysis of FMD was performed using the variation of radial artery flow during hyperaemia as an additional covariate. Analysis was performed only when ANOVA was considered significant using a modified paired Student's t test adjusted for multiple comparisons. In the exploratory study, the effect of the inhibitors on radial artery FMD and peak flow were analysed by ANOVA with inhibitors and subjects as factors and basal values of flow and diameter as a cofactor. P < 0.05 was considered statistically significant.
RESULTS
Randomized double-blind study
Systemic haemodynamic parameters
As shown in Table 1 , at 2 h after treatment, a significant decrease in MBP (P < 0.05) and HR (P < 0.001) was observed in both treatment groups. However, this decrease was not significantly different between the treatment groups. The local administration of l-NMMA did not modify the systemic haemodynamic parameters in either group (Table 2 ). 
Radial artery parameters at baseline
In the control period, telmisartan did not modify the basal radial artery flow and diameter compared with the placebo (Table 2) . l-NMMA did not modify the radial artery diameter, but decreased radial artery flow similarly in both treatment groups (both P < 0.05), suggesting a similar increase in local radial vascular resistance in the absence of a change in MBP.
Post-ischaemic hyperaemia
Deflation of the occlusion cuff was associated, in all cases, with an increase in radial artery flow ( Figure 1B ; P < 0.001). With regard to the hyperaemic stimulus in the control period, telmisartan did not modify either the peak flow or the AUC of flow (Figure 2) , and l-NMMA did not modify these parameters in either of the treatment groups ( Figure 2 ).
Radial artery FMD
Deflation of the occlusion cuff was associated, in all cases, with an increase in radial artery diameter ( Figure 1A ; P < 0.001). In the control period, radial artery FMD was not modified by telmisartan (9.9 + − 0.7 %) compared with placebo (10.9 + − 0.6 %; Figure 3 ). l-NMMA reduced the radial artery FMD in the placebo group (P < 0.05), but not in the telmisartan group (Figure 3) . Thus radial artery FMD after l-NMMA was enhanced by telmisartan (12.6 + − 1.2 %) compared with placebo (9.3 + − 0.8 %; P < 0.05).
Radial artery endothelium-independent dilatation
SNP induced a dose-dependent increase in radial artery blood flow ( Figure 4A ; P < 0.05) and diameter ( Figure 4B ; P < 0.001) in the two treatment groups, which was not modified by telmisartan. l-NMMA enhanced the increase in radial artery diameter at each dose of SNP to the same extent in both treatment groups (both P < 0.05) without affecting the increase in radial artery blood flow (Figure 4 ).
Complementary study
None of the inhibitors administrated affected the systemic haemodynamic parameters (Table 3) . Compared with control conditions before administration of telmisartan and the inhibitors, basal radial artery flow was not modified in telmisartan-treated subjects by aspirin, but was reduced to the same extent by aspirin + l-NMMA and aspirin + l-NMMA + fluconazole (both P < 0.05). The basal radial artery diameter, compared with control conditions before telmisartan administration, was not modified in telmisartan-treated subjects by aspirin or aspirin + l-NMMA, but was reduced by aspirin + l-NMMA + fluconazole (P < 0.05). Deflation of the occlusion cuff was associated, in all cases, with an increase in radial artery flow and diameter (both P < 0.001). The radial artery FMD, compared with control conditions before telmisartan administration, was not modified in telmisartan-treated subjects by aspirin or aspirin + l-NMMA, but was decreased by aspirin + l-NMMA + fluconazole (P < 0.05). Peak flow was not modified.
DISCUSSION
The main finding of the present study performed in healthy subjects was that acute AT 1 receptor blockade by telmisartan maintains peripheral conduit artery FMD during local NOS inhibition, which suggests the development of a compensatory endothelial mechanism to prevent the effects of a decrease in NO availability. This effect of AT 1 receptor blockade on the endothelium-dependent dilatation of conduit arteries appears to be independent of PGI 2 availability and could in fact be related to an increase in the release of an EDHF. This double-bind study was designed to explore, in healthy subjects, the effect of AT 1 receptor blockade on the FMD of the radial artery, a model of peripheral conduit artery [1, 2, 12, [19] [20] [21] [22] 28] , before and during induced NO deficiency. In the placebo-treated group, local NOS inhibition induced using l-NMMA decreased basal radial artery flow without modifying radial artery diameter, confirming, in the absence of a change in MBP, the role of NO in the control of the basal vascular resistance in humans [1, 12, [19] [20] [21] 28] . In addition, l-NMMA enhanced radial artery dilatation to SNP, demonstrating a hypersensitivity of the smooth muscle cells to exogenous NO, which has been observed previously both in vitro [29] and in vivo [19] [20] [21] . In fact, removal of the endogenous NO-mediated vasodilator tone in conduit arteries has been shown to lead to a specific hypersensitivity to exogenous NO provided by nitrovasodilators [29] . Thus this result demonstrates, under experimental conditions, an effective inhibition of NO release by l-NMMA in the radial artery wall. In contrast, the increase in radial artery blood flow in response to SNP infusion was not affected by l-NMMA. As reported previously [21] , this could be related to the weak vasodilator effect observed with SNP infusion in resistance arteries. Furthermore, l-NMMA decreased radial artery FMD in the placebo group, demonstrating the role of NO in endotheliumdependent dilatation of peripheral conduit arteries in response to a sustained increase in flow induced by a prolonged period of ischaemia (10 min) [19, 21] . However, this decrease in the magnitude of FMD was only 15 % Table 3 when compared with experiments that have demonstrated previously a major role of NO in this response using shorter periods of ischaemia (3-8 min) [1, 2, 28] . This reduced effect could result from the dose of l-NMMA being insufficient to fully inhibit eNOS (endothelial NOS). Moreover, as emphasized previously [2] , this moderate decrease in FMD after l-NMMA could also be explained by a decrease in the role of NO in peripheral conduit artery FMD during sustained hyperaemic stimulation, suggesting the involvement of other endothelial vasodilator factors under these experimental conditions. Furthermore, in accordance with previous findings [1, 2, 27, 30, 31] , l-NMMA did not modify radial artery peak flow during hyperaemia, supporting the absence of a contribution of NO in the maximal arteriolar vasodilatation in response to forearm ischaemia. In addition, l-NMMA did not decrease the duration of hyperaemia further in the present study, in contrast with previous results obtained with a brief duration of ischaemia [1, 2, 28] . A similar negative result was also reported after a 15 min duration of ischaemia [2] and could be related to the decrease in the relative contribution of NO compared with the direct effect of adenosine in the late phase of the increase in flow during sustained hyperaemia [30] .
With regards to the acute blockade of the AT 1 receptor, this was induced by telmisartan, a high-affinity antagonist, administered orally at a single dose of 80 mg, which represents the maximal therapeutic dose [32, 33] . Systemic haemodynamic and vascular parameters were obtained 2 h after treatment, corresponding to the time of the maximal inhibitory effect of the drug and during the first 2 h of its maximal activity [32] . In fact, a single administration of this dose of telmisartan has been shown to prevent, in healthy volunteers, 90 % of the pressure increase in response to exogenous angiotensin II [32] , demonstrating that under similar conditions as in the present study an effective and near-maximal degree of AT 1 receptor blockade. As expected from our population, acute AT 1 receptor blockade caused a small, but nonsignificant, decrease in BP [32] . In fact, this absence of a decrease in BP, which was also observed by Stangier et al. [32] , is not an indicator of a non-significant AT 1 receptor blockade, but confirms the absence or the minor involvement of the renin-angiotensin system in the short-term regulation of BP in sodium-replete healthy subjects [34, 35] . However, as a negative relationship was demonstrated between BP and the magnitude of conduit artery FMD, we used BP as a covariate in the statistical analysis to avoid any passive effect of this parameter on the responses observed [36] . During the control period, telmisartan did not significantly modify the radial artery flow at baseline or the hyperaemic response, confirming that the renin-angiotensin system, under physiological conditions, was not involved in the acute control of basal and post-ischaemic peripheral vascular tone [14, 28, 34, 35] . Moreover, telmisartan did not modify the magnitude of radial artery FMD, as reported previously [37] in healthy subjects using repeated administration of losartan and the ACE (angiotensin-converting enzyme) inhibitor quinapril. In contrast, during eNOS inhibition, acute AT 1 receptor blockade prevented the decrease in the radial artery FMD observed in the placebo-treated group. This effect was not related to a modification in the sensitivity of smooth muscle cells after AT 1 receptor antagonist administration, because the endotheliumindependent dilatation assessed by SNP was comparable in both treatment groups before and after l-NMMA. In addition, it appears unlikely that telmisartan could have increased the release of NO during FMD by enhancing eNOS activity to a level which makes this enzyme insensitive to the dose of l-NMMA administered. In fact, persistence of the hypersensitivity to SNP observed in the telmisartan group after l-NMMA demonstrated the effective decrease of NO availability in the arterial wall. Moreover, the magnitude of this hypersensitivity was similar to that after placebo, which demonstrated that, even if not maximal, a stable level of NOS inhibition was achieved in both treatment groups. This last point shows that maintaining FMD during NOS inhibition following AT 1 receptor blockade was not related to the increase in NO availability. Furthermore, this effect was not related to an increase in the hyperaemic stimulus, because telmisartan did not significantly affect peak flow or the duration of the increase in flow. Therefore this result suggests the development of a compensatory endothelial mechanism after AT 1 receptor antagonist administration, probably an increase in the release by the endothelium in response to flow of an other vasodilator factor to compensate for the loss of NO synthesis. It is unlikely that telmisartan increased the release of PGI 2 under our present conditions as we observed, in the complementary study, that the COX inhibitor aspirin administered alone or in combination with l-NMMA no longer had any effect on radial artery FMD in the healthy subjects treated with the AT 1 receptor antagonist when compared with the controls. This result is consistent with previous findings showing that a compensatory increase in PGI 2 release was only observed after chronic NOS inhibition in animals [38] and that the inhibition of COX did not modify radial artery FMD in response to sustained and non-sustained hyperaemic stimulations, even in the presence of l-NMMA [1, 2] .
As the combined inhibition of NO and PGI 2 synthesis did not affect radial artery FMD in the telmisartan-treated volunteers, the beneficial effect of AT 1 receptor blockade on conduit artery endothelial vasomotor function during induced NO deficiency could be explained by the increase in the release of an EDHF. This hypothesis is consistent with previous studies performed in aged and hypertensive animals and in experimental renal failure, demonstrating that AT 1 receptor antagonist administration can enhance EDHF-mediated dilatation of mesenteric arteries in response to acetylcholine during NOS and COX inhibition [16, 17, 39] . Although the EDHF involved in this effect has not been identified, we co-infused fluconazole with l-NMMA to evaluate the role of CYP epoxygenases in radial artery FMD during AT 1 receptor blockade. In fact, previous ex vivo studies have shown that FMD is mediated by CYP-related metabolites during NO deficiency in human coronary and mouse mesenteric arterioles [40, 41] . In addition, an interaction between NO and an endothelial CYP-dependent vasodilator pathway participates in the regulation of exercise-induced skeletal muscle blood flow in humans in vivo [42] . Under these conditions, basal radial artery diameter was reduced by the combination of aspirin, l-NMMA and fluconazole. Our previous study performed in healthy subjects without treatment [20] revealed a role of a CYP-related EDHF in the regulation of radial artery diameter at baseline. During reactive hyperaemia with combined blockade of both NO and PGI 2 synthesis, the infusion of fluconazole was associated with a smaller increase in diameter with no modification in peak flow compared with the control group. This demonstrates for the first time that a CYP-dependent vasodilator pathway is involved under these experimental conditions in human peripheral conduit artery FMD. Although the reduction in the magnitude of radial artery FMD via the addition of fluconazole in subjects treated with telmisartan was similar to that observed after l-NMMA in the placebo group, additional experiments are required to confirm whether the administration of AT 1 receptor antagonists increases the influence of a CYP-dependent vasodilator pathway in maintaining conduit artery FMD during the loss of NO synthesis in humans.
Furthermore, it would be interesting to evaluate if the alternative endothelial mechanism involved in the beneficial effect of AT 1 receptor blockade could compensate for a greater magnitude of decrease in NO-dependent FMD similar to that provided by l-NMMA during shorter occlusion periods. In addition, whether the development of this NO-and PGI 2 -independent mechanism following the administration of AT 1 receptor antagonists is effective in pathological states characterized by a decrease in NO availability warrants further investigation. This effect could be particularly important in maintaining an adequate vascular conductance and cardiovascular coupling, and to limit the progression of cardiovascular diseases, in particular atherosclerosis.
Conclusions
The results of the present study demonstrate that acute AT 1 receptor blockade opposes the decrease in conduit artery FMD during induced NO deficiency in humans, suggesting the development of a compensatory endothelial mechanism. Although this mechanism is independent of PGI 2 , it may be related to the release of an EDHF.
